ENANTA PHARMACEUTICALS INC
ENTA evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $393.2M
- Lead Asset:
- EDP-938 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ENTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENTA
Enanta Pharmaceuticals is a biopharmaceutical company focused on discovering and developing small-molecule drugs for virology (RSV) and immunology (mast cell-mediated diseases), with an approved HCV product partnered with AbbVie.
Key risk: Cash burn rate
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$393.2M
Cash Runway
—
Lead Asset
EDP-938 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 309 clinical trials for ENANTA PHARMACEUTICALS INC.
Similar companies
Enanta Pharmaceuticals is a biopharmaceutical company focused on discovering and developing small-molecule drugs for virology (RSV) and immunology (mast cell-mediated diseases), with an approved HCV product partnered with AbbVie.
- Cash & equivalents of $33.4M as of 2026-06-30 [sec].
- Total revenue of $14.4M and net income of -$19.5M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $101.1M as of 2026-06-30 [sec].
- Lead RSV candidate zelicapavir is in Phase 2b trials for high-risk adults (RESOLVE) and pediatrics (LOTUS), with topline data expected in 2027 [sec_mda · as of 2026-08-12].
- Lead immunology candidate EDP-978, an oral KIT inhibitor, is in Phase 1 clinical trials [sec_mda · as of 2026-08-12].
What works
- Approved HCV product MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir) is marketed by partner AbbVie, providing a royalty revenue stream [pipeline].
- RSV program has two clinical candidates (zelicapavir and EDP-323) advancing into Phase 2b trials, targeting high-risk populations with significant unmet need [sec_mda · as of 2026-08-12].
- Immunology program has a clinical-stage KIT inhibitor (EDP-978) with potent in vitro and in vivo activity, addressing large markets like chronic urticaria and atopic dermatitis [sec_mda · as of 2026-08-12].
- Company has funded operations through AbbVie royalties and a $200M royalty sale payment in April 2023, providing non-dilutive capital [sec_mda · as of 2026-08-12].
What to weigh
- Net income was -$19.5M for the period ending 2026-06-30, indicating ongoing operating losses [sec].
- Cash & equivalents decreased from $227.0M as of 2026-03-31 to $33.4M as of 2026-06-30, a significant reduction [sec_mda · as of 2026-05-13] [sec].
- R&D expenses are expected to increase in the next 12 months due to RSV clinical trials, adding to cash burn [sec_mda · as of 2026-08-12].
- All immunology and most virology programs are in early-to-mid stage clinical development, with no near-term revenue from new products expected [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had $211.5 million in cash, cash equivalents and short-term and long-term marketable securit”
SEC MD&A · August 12, 2026
Zelicapavir Phase 2b adult study (RESOLVE) initiation and data timeline
“We expect to initiate this study named RESOLVE in the fourth quarter of 2026, with data from the Phase 2b portion of the RESOLVE study targeted for 2027.”
SEC MD&A · August 12, 2026
EDP-978 is a clinical-stage KIT inhibitor
“We have selected EDP-978 as our clinical candidate. EDP-978 demonstrates potent nanomolar activity in both binding and cellular function assays”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Cash burn rate — Cash & equivalents dropped from $227M (Mar 2026) to $33.4M (Jun 2026), a rapid decline that may require near-term financing [sec_mda · as of 2026-05-13] [sec].
- R&D expense increase — R&D expenses expected to rise in next 12 months due to RSV trials, accelerating cash consumption [sec_mda · as of 2026-08-12].
- No near-term product revenue — All new pipeline candidates are in Phase 1 or Phase 2; no new product revenue expected for several years [sec_mda · as of 2026-08-12].
- Dependence on AbbVie royalties — Operations funded primarily by AbbVie royalties and a one-time $200M royalty sale; future royalty income may decline [sec_mda · as of 2026-08-12].
What to watch
- Initiation of RESOLVE Phase 2b study for zelicapavir in high-risk adults in Q4 2026 [sec_mda · as of 2026-08-12].
- Topline data from zelicapavir Phase 2b studies (RESOLVE and LOTUS) expected in 2027 [sec_mda · as of 2026-08-12].
- Phase 1 data for EDP-978 (KIT inhibitor) and potential selection of next immunology development candidate in H2 2026 [sec_mda · as of 2026-08-12].
- Cash runway and any potential financing or partnership announcements given the sharp decline in cash reserves [sec].
Sources: Catalysts · Pipeline · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run ENANTA PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ENANTA PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.94 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 8.9%
- Days to cover
- 18.2
- Shares short
- 2,155,192
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENTA short interestGovernance
Frequently asked questions
What is the AI investment thesis for ENANTA PHARMACEUTICALS INC?
Enanta Pharmaceuticals is a biopharmaceutical company focused on discovering and developing small-molecule drugs for virology (RSV) and immunology (mast cell-mediated diseases), with an approved HCV product partnered with AbbVie.
What is ENANTA PHARMACEUTICALS INC's lead drug candidate?
ENANTA PHARMACEUTICALS INC's most advanced tracked candidate is EDP-938 (Phase 2) for Respiratory Syncytial Virus (RSV); RSV Infection.
Who is the CEO of ENANTA PHARMACEUTICALS INC?
Dr. Jay R. Luly Ph.D. is the chief executive officer of ENANTA PHARMACEUTICALS INC (ENTA).
Where is ENANTA PHARMACEUTICALS INC headquartered?
ENANTA PHARMACEUTICALS INC (ENTA) is headquartered in Watertown, MA, United States.
What therapeutic areas does ENANTA PHARMACEUTICALS INC focus on?
ENANTA PHARMACEUTICALS INC develops therapies across Oncology, Rare Disease, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Endocrinology, Reproductive, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.